Cargando…

Infective Endocarditis Risk with Melody versus Sapien Valves Following Transcatheter Pulmonary Valve Implantation: A Systematic Review and Meta-Analysis of Prospective Cohort Studies

Background: Transcatheter pulmonary valve implantation (TPVI) is an effective non-surgical treatment method for patients with right ventricle outflow tract dysfunction. The Medtronic Melody and the Edwards Sapien are the two valves approved for use in TPVI. Since TPVI patients are typically younger,...

Descripción completa

Detalles Bibliográficos
Autores principales: Machanahalli Balakrishna, Akshay, Dilsaver, Danielle B., Aboeata, Ahmed, Gowda, Ramesh M., Goldsweig, Andrew M., Vallabhajosyula, Saraschandra, Anderson, Jason H., Simard, Trevor, Jhand, Aravdeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419461/
https://www.ncbi.nlm.nih.gov/pubmed/37568289
http://dx.doi.org/10.3390/jcm12154886
_version_ 1785088523423973376
author Machanahalli Balakrishna, Akshay
Dilsaver, Danielle B.
Aboeata, Ahmed
Gowda, Ramesh M.
Goldsweig, Andrew M.
Vallabhajosyula, Saraschandra
Anderson, Jason H.
Simard, Trevor
Jhand, Aravdeep
author_facet Machanahalli Balakrishna, Akshay
Dilsaver, Danielle B.
Aboeata, Ahmed
Gowda, Ramesh M.
Goldsweig, Andrew M.
Vallabhajosyula, Saraschandra
Anderson, Jason H.
Simard, Trevor
Jhand, Aravdeep
author_sort Machanahalli Balakrishna, Akshay
collection PubMed
description Background: Transcatheter pulmonary valve implantation (TPVI) is an effective non-surgical treatment method for patients with right ventricle outflow tract dysfunction. The Medtronic Melody and the Edwards Sapien are the two valves approved for use in TPVI. Since TPVI patients are typically younger, even a modest annual incidence of infective endocarditis (IE) is significant. Several previous studies have shown a growing risk of IE after TPVI. There is uncertainty regarding the overall incidence of IE and differences in the risk of IE between the valves. Methods: A systematic search was conducted in the MEDLINE, EMBASE, PubMed, and Cochrane databases from inception to 1 January 2023 using the search terms ‘pulmonary valve implantation’, ‘TPVI’, or ‘PPVI’. The primary outcome was the pooled incidence of IE following TPVI in Melody and Sapien valves and the difference in incidence between Sapien and Melody valves. Fixed effect and random effect models were used depending on the valve. Meta-regression with random effects was conducted to test the difference in the incidence of IE between the two valves. Results: A total of 22 studies (including 10 Melody valve studies, 8 Sapien valve studies, and 4 studies that included both valves (572 patients that used the Sapien valve and 1395 patients that used the Melody valve)) were used for the final analysis. Zero IE incidence following TPVI was reported by eight studies (66.7%) that utilized Sapien valves compared to two studies (14.3%) that utilized Melody valves. The pooled incidence of IE following TPVI with Sapien valves was 2.1% (95% CI: 0.9% to 5.13%) compared to 8.5% (95% CI: 4.8% to 15.2%) following TPVI with Melody valves. Results of meta-regression indicated that the Sapien valve had a 79.6% (95% CI: 24.2% to 94.4%, p = 0.019; R(2) = 34.4) lower risk of IE incidence compared to the Melody valve. Conclusions: The risk of IE following TPVI differs significantly. A prudent valve choice in favor of Sapien valves to lower the risk of post-TPVI endocarditis may be beneficial.
format Online
Article
Text
id pubmed-10419461
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104194612023-08-12 Infective Endocarditis Risk with Melody versus Sapien Valves Following Transcatheter Pulmonary Valve Implantation: A Systematic Review and Meta-Analysis of Prospective Cohort Studies Machanahalli Balakrishna, Akshay Dilsaver, Danielle B. Aboeata, Ahmed Gowda, Ramesh M. Goldsweig, Andrew M. Vallabhajosyula, Saraschandra Anderson, Jason H. Simard, Trevor Jhand, Aravdeep J Clin Med Article Background: Transcatheter pulmonary valve implantation (TPVI) is an effective non-surgical treatment method for patients with right ventricle outflow tract dysfunction. The Medtronic Melody and the Edwards Sapien are the two valves approved for use in TPVI. Since TPVI patients are typically younger, even a modest annual incidence of infective endocarditis (IE) is significant. Several previous studies have shown a growing risk of IE after TPVI. There is uncertainty regarding the overall incidence of IE and differences in the risk of IE between the valves. Methods: A systematic search was conducted in the MEDLINE, EMBASE, PubMed, and Cochrane databases from inception to 1 January 2023 using the search terms ‘pulmonary valve implantation’, ‘TPVI’, or ‘PPVI’. The primary outcome was the pooled incidence of IE following TPVI in Melody and Sapien valves and the difference in incidence between Sapien and Melody valves. Fixed effect and random effect models were used depending on the valve. Meta-regression with random effects was conducted to test the difference in the incidence of IE between the two valves. Results: A total of 22 studies (including 10 Melody valve studies, 8 Sapien valve studies, and 4 studies that included both valves (572 patients that used the Sapien valve and 1395 patients that used the Melody valve)) were used for the final analysis. Zero IE incidence following TPVI was reported by eight studies (66.7%) that utilized Sapien valves compared to two studies (14.3%) that utilized Melody valves. The pooled incidence of IE following TPVI with Sapien valves was 2.1% (95% CI: 0.9% to 5.13%) compared to 8.5% (95% CI: 4.8% to 15.2%) following TPVI with Melody valves. Results of meta-regression indicated that the Sapien valve had a 79.6% (95% CI: 24.2% to 94.4%, p = 0.019; R(2) = 34.4) lower risk of IE incidence compared to the Melody valve. Conclusions: The risk of IE following TPVI differs significantly. A prudent valve choice in favor of Sapien valves to lower the risk of post-TPVI endocarditis may be beneficial. MDPI 2023-07-25 /pmc/articles/PMC10419461/ /pubmed/37568289 http://dx.doi.org/10.3390/jcm12154886 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Machanahalli Balakrishna, Akshay
Dilsaver, Danielle B.
Aboeata, Ahmed
Gowda, Ramesh M.
Goldsweig, Andrew M.
Vallabhajosyula, Saraschandra
Anderson, Jason H.
Simard, Trevor
Jhand, Aravdeep
Infective Endocarditis Risk with Melody versus Sapien Valves Following Transcatheter Pulmonary Valve Implantation: A Systematic Review and Meta-Analysis of Prospective Cohort Studies
title Infective Endocarditis Risk with Melody versus Sapien Valves Following Transcatheter Pulmonary Valve Implantation: A Systematic Review and Meta-Analysis of Prospective Cohort Studies
title_full Infective Endocarditis Risk with Melody versus Sapien Valves Following Transcatheter Pulmonary Valve Implantation: A Systematic Review and Meta-Analysis of Prospective Cohort Studies
title_fullStr Infective Endocarditis Risk with Melody versus Sapien Valves Following Transcatheter Pulmonary Valve Implantation: A Systematic Review and Meta-Analysis of Prospective Cohort Studies
title_full_unstemmed Infective Endocarditis Risk with Melody versus Sapien Valves Following Transcatheter Pulmonary Valve Implantation: A Systematic Review and Meta-Analysis of Prospective Cohort Studies
title_short Infective Endocarditis Risk with Melody versus Sapien Valves Following Transcatheter Pulmonary Valve Implantation: A Systematic Review and Meta-Analysis of Prospective Cohort Studies
title_sort infective endocarditis risk with melody versus sapien valves following transcatheter pulmonary valve implantation: a systematic review and meta-analysis of prospective cohort studies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419461/
https://www.ncbi.nlm.nih.gov/pubmed/37568289
http://dx.doi.org/10.3390/jcm12154886
work_keys_str_mv AT machanahallibalakrishnaakshay infectiveendocarditisriskwithmelodyversussapienvalvesfollowingtranscatheterpulmonaryvalveimplantationasystematicreviewandmetaanalysisofprospectivecohortstudies
AT dilsaverdanielleb infectiveendocarditisriskwithmelodyversussapienvalvesfollowingtranscatheterpulmonaryvalveimplantationasystematicreviewandmetaanalysisofprospectivecohortstudies
AT aboeataahmed infectiveendocarditisriskwithmelodyversussapienvalvesfollowingtranscatheterpulmonaryvalveimplantationasystematicreviewandmetaanalysisofprospectivecohortstudies
AT gowdarameshm infectiveendocarditisriskwithmelodyversussapienvalvesfollowingtranscatheterpulmonaryvalveimplantationasystematicreviewandmetaanalysisofprospectivecohortstudies
AT goldsweigandrewm infectiveendocarditisriskwithmelodyversussapienvalvesfollowingtranscatheterpulmonaryvalveimplantationasystematicreviewandmetaanalysisofprospectivecohortstudies
AT vallabhajosyulasaraschandra infectiveendocarditisriskwithmelodyversussapienvalvesfollowingtranscatheterpulmonaryvalveimplantationasystematicreviewandmetaanalysisofprospectivecohortstudies
AT andersonjasonh infectiveendocarditisriskwithmelodyversussapienvalvesfollowingtranscatheterpulmonaryvalveimplantationasystematicreviewandmetaanalysisofprospectivecohortstudies
AT simardtrevor infectiveendocarditisriskwithmelodyversussapienvalvesfollowingtranscatheterpulmonaryvalveimplantationasystematicreviewandmetaanalysisofprospectivecohortstudies
AT jhandaravdeep infectiveendocarditisriskwithmelodyversussapienvalvesfollowingtranscatheterpulmonaryvalveimplantationasystematicreviewandmetaanalysisofprospectivecohortstudies